Bone health in inflammatory bowel disease.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2023-07-01 Epub Date: 2023-08-20 DOI:10.1080/17474124.2023.2248874

Hao Wei, Yihan Zhao, Lisha Xiang

{"title":"Bone health in inflammatory bowel disease.","authors":"Hao Wei, Yihan Zhao, Lisha Xiang","doi":"10.1080/17474124.2023.2248874","DOIUrl":null,"url":null,"abstract":"Introduction: Inflammatory bowel disease (IBD) is a chronic disease characterized by the presence of systemic inflammation, manifesting not only as gastrointestinal symptoms but also as extraintestinal bone complications, including osteopenia and osteoporosis. However, the association between IBD and osteoporosis is complex, and the presence of multifactorial participants in the development of osteoporosis is increasingly recognized. Unlike in adults, delayed puberty and growth hormone/insulin-like growth factor-1 axis abnormalities are essential risk factors for osteoporosis in pediatric patients with IBD.Areas covered: This article reviews the potential pathophysiological mechanisms contributing to osteoporosis in adult and pediatric patients with IBD and provides evidence for effective prevention and treatment, focusing on pediatric patients with IBD. A search was performed from PubMed and Web of Science inception to February 2023 to identify articles on IBD, osteoporosis, pediatric, and fracture risk.Expert opinion: A comprehensive treatment pattern based on individualized principles can be used to manage pediatric IBD-related osteoporosis.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"921-935"},"PeriodicalIF":3.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2023.2248874","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inflammatory bowel disease (IBD) is a chronic disease characterized by the presence of systemic inflammation, manifesting not only as gastrointestinal symptoms but also as extraintestinal bone complications, including osteopenia and osteoporosis. However, the association between IBD and osteoporosis is complex, and the presence of multifactorial participants in the development of osteoporosis is increasingly recognized. Unlike in adults, delayed puberty and growth hormone/insulin-like growth factor-1 axis abnormalities are essential risk factors for osteoporosis in pediatric patients with IBD.

Areas covered: This article reviews the potential pathophysiological mechanisms contributing to osteoporosis in adult and pediatric patients with IBD and provides evidence for effective prevention and treatment, focusing on pediatric patients with IBD. A search was performed from PubMed and Web of Science inception to February 2023 to identify articles on IBD, osteoporosis, pediatric, and fracture risk.

Expert opinion: A comprehensive treatment pattern based on individualized principles can be used to manage pediatric IBD-related osteoporosis.

查看原文本刊更多论文

炎症性肠病的骨骼健康。

引言：炎症性肠病（IBD）是一种以全身炎症为特征的慢性疾病，不仅表现为胃肠道症状，还表现为肠外骨并发症，包括骨质减少和骨质疏松。然而，IBD与骨质疏松症之间的关系是复杂的，骨质疏松症发展过程中多因素参与者的存在越来越受到人们的认可。与成人不同，青春期延迟和生长激素/胰岛素样生长因子-1轴异常是儿童IBD患者骨质疏松症的重要危险因素。涵盖领域：本文综述了成人和儿童IBD患者骨质疏松症的潜在病理生理机制，并为有效预防和治疗提供了证据，重点关注儿童IBD病人。从PubMed和Web of Science成立到2023年2月进行了搜索，以确定关于IBD、骨质疏松症、儿科和骨折风险的文章。专家意见：基于个体化原则的综合治疗模式可用于治疗儿童IBD相关骨质疏松症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.